•
Dec 31, 2021

Medpace Q4 2021 Earnings Report

Medpace's Q4 2021 financial results were reported, showing revenue growth and strategic advancements.

Key Takeaways

Medpace Holdings, Inc. announced its Q4 and full year 2021 financial results, with Q4 revenue reaching $308.6 million, an 18.8% increase year-over-year, and net new business awards totaling $458.7 million, up 27.9% from the previous year. GAAP net income for Q4 was $50.0 million, or $1.32 per diluted share. The company provided financial guidance for 2022, forecasting revenue between $1.400 billion and $1.460 billion.

Q4 2021 revenue increased by 18.8% to $308.6 million compared to Q4 2020.

Net new business awards for Q4 2021 rose by 27.9% to $458.7 million, resulting in a book-to-bill ratio of 1.49x.

GAAP net income for Q4 2021 was $50.0 million, or $1.32 per diluted share.

The company forecasts 2022 revenue in the range of $1.400 billion to $1.460 billion.

Total Revenue
$309M
Previous year: $260M
+18.8%
EPS
$1.32
Previous year: $1.35
-2.2%
Net New Business Awards
$459M
Previous year: $359M
+27.9%
Backlog
$2B
Gross Profit
$88M
Previous year: $82.9M
+6.2%
Cash and Equivalents
$461M
Previous year: $278M
+66.1%
Free Cash Flow
$61.8M
Previous year: $97.7M
-36.8%
Total Assets
$1.66B
Previous year: $1.39B
+19.4%

Medpace

Medpace

Forward Guidance

The Company forecasts 2022 revenue in the range of $1.400 billion to $1.460 billion, representing growth of 22.6% to 27.8% over 2021 revenue of $1.142 billion. GAAP net income for full year 2022 is forecasted in the range of $204.0 million to $216.0 million. Additionally, full year 2022 EBITDA is expected in the range of $262.0 million to $278.0 million.